Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
  • English
    • 日本語
Evaluate Logo

navigation

  • What We Do
  • Vantage
    • News
    • Analysis
    • Policy & Pricing
    • Data Insights
    • Events
    • Medtech
    • Therapy Areas
    • About Vantage
      • Editorial team
  • Products & Services
    • Consensus Forecasts
    • Pharma
      • EvaluatePharma
      • EvaluatePharma Vision
    • Custom Solutions
    • How We Can Help You
      • Pharma and Biotech
      • Medtech
      • Financial Services
      • Management Consultancies
      • Service Providers
    • Client Success
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Media Centre
      • Press Releases
      • Media Coverage
    • Executive Team
    • Vision & History
  • Careers
    • Current Vacancies
  • Contact Us
  • Sign Up for Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Policy & Pricing
    • Policy & Regulation
    • Pricing
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Primary tabs

  • View(active tab)

Regeneron Pharmaceuticals

Thumbnail
February 11, 2019

Regeneron and Sanofi play follow the leader on Praluent pricing

Amgen has set the stage for low-hassle access to new cholesterol-lowering agents, leaving little choice for competitors.

Thumbnail
February 07, 2019

Sanofi does a spring clean

The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.

Article image
Vantage logo
January 15, 2019

Big pharma consolidation: the tectonic plates shift

The takeover of Celgene has disrupted pharma’s conventional wisdom on which companies should merge and when. This is how things now stand.

Article image
Vantage logo
January 14, 2019

Why Novo Nordisk should buy Amarin

Pfizer is said to be interested in Amarin, but the Danish group’s need for a growth injection is greater.

Article image
Vantage logo
January 08, 2019

JP Morgan 2019 day one roundup – happy days are here again

The takeovers of Loxo and Celgene put M&A back on the agenda, and positive clinical readouts from Sage and Axsome add to the celebratory mood.

Article image
Vantage logo
January 02, 2019

JP Morgan preview – price hikes come back with a bang in 2019

Allergan, Biogen, Bristol-Myers Squibb and Lilly follow Pfizer and Merck & Co on price increases, and there could be more to come at JP Morgan.

Article image
Vantage logo
December 18, 2018

Achillion’s first oral Soliris rival hits the buffers

Achillion’s pivot to a next-gen project in paroxysmal nocturnal haemoglobinuria is an admission that its first attempt to compete with Alexion’s Soliris has fallen short.

Article image
Vantage logo
December 14, 2018

Upcoming events – Verona waits to exhale and a new test for Alexion

Verona Pharma needs another COPD win, while Alexion seeks a new use for its Soliris successor.

Article image
Vantage logo
December 12, 2018

Ra joins the challenge to Alexion’s Soliris stranglehold

Promising data in myasthenia gravis, plus a pledge to compete on price, means that Ra Pharmaceuticals’ zilucoplan could soon give Alexion a headache – and others are…

Article image
Vantage logo
December 06, 2018

Ash 2018 event analyzer – Losers edge out winners in year’s final major meeting

Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.

Article image
Vantage logo
November 09, 2018

Biotech's big-bucks buybacks begin to burn

If big biotech cannot deliver innovation investors might start demanding shareholder payout plans that look more like big pharma's.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

December 13, 2018

Vantage 2019 Preview

November 27, 2018

First-line lung cancer: can Keytruda be stopped?

Editor's Picks

Vantage logo
January 22, 2019

Gene therapy: how much will it cost patients?

Vantage logo
January 25, 2019

Last year’s new medicines reveal strong commercial promise and some novelty

Vantage logo
January 21, 2019

Roche dominates 2019’s big patent expiries

Vantage logo
January 24, 2019

Bristol makes investors squirm a little more

Vantage logo
January 22, 2019

J&J’s dour outlook spells trouble for biopharma

Open modal

Evaluate HQ +44-(0)20-7377-0800

Evaluate Americas +1-617-573-9450

Evaluate APAC +81 (0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

Follow Us

© Copyright 2019 Evaluate Ltd.